Key Drivers
- Strong Margins
- Heavy Leverage
- Cash Conversion
AIAI Summary
IRWD now looks like a real earnings-and-cash-generating story rather than a cash-burning biotech, but the re-rating is fragile because the improved outlook is heavily dependent on LINZESS and vulnerable to reimbursement, patent, and execution risks that could quickly compress margins and sentiment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Heavy Leverage
- •Cash Conversion
IRWD's latest quarter shows strong profitability and a reasonable earnings-based valuation, but heavy debt, negative equity, and weaker cash conversion remain the main risks.
Price Behavior
Key Price Behavior Insights:
- •Range-bound action
- •Buy-the-dip support
- •Weakening momentum
IRWD is essentially flat over the last month, with buyers defending the $3.50–$3.68 support zone, but it still needs to break above $4.09–$4.22 to confirm a real recovery from the post-$4.83 slide.
Sharp peak to $4.83 on 2026-05-06 followed by lower highs and lower lows
Sentiment & News
Key News Insights:
- •LINZESS growth
- •Management turnover
- •Pipeline progress
Ironwood delivered a solid Q1 beat with strong LINZESS growth and reaffirmed guidance, but shares remain pressured by management turnover, insider selling, and longer-term pricing/generic risks despite pipeline progress.
The news is moderately positive operationally, but near-term sentiment for IRWD remains capped by governance concerns and future revenue risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings